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Introduction
Hospitals worldwide are facing the growing presence of infections caused by antimicrobial-resistant and multidrug-resistant (MDR) pathogens. 1 -5 Pathogens including methicillin-resistant Staphylococcus aureus (MRSA) [both community-associated (CA-MRSA) and healthcare-associated (HA-MRSA)], vancomycin-resistant Enterococcus species (VRE), penicillin-resistant Streptococcus pneumoniae, extended-spectrum b-lactamase (ESBL)-producing Escherichia coli and Klebsiella species, and fluoroquinolone-resistant and carbapenem-resistant Enterobacteriaceae, and Pseudomonas aeruginosa are growing in prevalence globally. 1 -6 Treatment options for antimicrobialresistant organisms can be severely limited, as these organisms frequently display an MDR phenotype. 1, 7 We recently reported on the prevalence of antimicrobialresistant pathogens in Canadian hospitals 5 as well as the # The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
Antimicrobial susceptibility testing
Following two subcultures from frozen stock, the in vitro activity of selected antimicrobials was determined by broth microdilution in accordance with CLSI guidelines. 8 Antimicrobial agents were obtained as laboratory-grade powders from their respective manufacturers. Stock solutions were prepared and dilutions made as described by CLSI. 8 The MICs for the isolates were determined using 96-well customdesigned microtitre plates. These plates contained doubling antimicrobial dilutions in 100 mL/well of cation-adjusted Mueller -Hinton broth and were inoculated to achieve a final concentration of 5×10 5 cfu/mL. The plates were then incubated in ambient air for 24 h prior to reading. Colony counts were performed periodically to confirm inocula. Quality control was performed using ATCC quality control organisms, including S. pneumoniae 49619, S. aureus 29213, Enterococcus faecalis 29212, E. coli 25922 and P. aeruginosa 27853.
Antimicrobial MIC interpretive standards were defined according to CLSI breakpoints. 9 The following interpretive breakpoints (FDA) were used for tigecycline [susceptible (S), intermediate (I) and resistant (R) isolates]: S. aureus [methicillin-susceptible (MSSA) and MRSA], ≤0.5 mg/L (S); E. faecalis (vancomycin susceptible), ≤0.25 mg/L (S); and Enterobacteriaceae, ≤2 mg/L (S), 4 mg/L (I) and ≥8 mg/L (R). The following interpretive breakpoints (FDA) were used for telavancin: S. aureus (MSSA and MRSA), ≤1.0 mg/L (S); and Streptococcus pyogenes and Streptococcus agalactiae, ≤0.12 mg/L (S).
Of the 27123 organisms collected, 22746 (83.9%) underwent susceptibility testing. Isolates selected for susceptibility testing included the top 20 pathogens [although not all coagulase-negative staphylococci (CoNS) or any viridans streptococci were tested] as well as a variety of less common Gram-negative bacilli. The development of a centralized database for the CANWARD study results was undertaken by International Health Management Associates, Schaumburg, IL, USA.
Characterization of MRSA isolates
Screening for methicillin resistance was performed using CLSI-approved disc diffusion with cefoxitin 9 as well as by growth on MRSA Select chromogenic media (Bio-Rad Laboratories Ltd, Mississauga, Ontario, Canada). Potential MRSA isolates were confirmed by mecA PCR, as previously described. 10 All isolates of MRSA were typed using staphylococcal protein A (spa) typing to assess whether the isolates were CA or HA genotypes. 10, 11 Isolates with a spa type associated with C(Canadian)MRSA7 or CMRSA10 were considered CA-MRSA. Isolates with a spa type associated with CMRSA1, CMRSA2, CMRSA4, CMRSA5, CMRSA3/6, CMRSA8 or CMRSA9 were considered HA-MRSA. 11 Characterization of ESBL-producing E. coli isolates Potential E. coli ESBL producers were identified as isolates with a ceftriaxone and/or ceftazidime MIC of ≥1 mg/L and confirmed using the CLSI double-disc diffusion method, as previously described. 12 
Characterization of VRE isolates
Potential VRE isolates were confirmed by vanA and vanB PCR, as previously described. 
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Results
Patient demographics and specimen types
Most common organisms isolated
Of the 27 123 organisms collected, the 20 most common species accounted for 89.4% of the total (n¼ 24 235) ( Table 1 
Antimicrobial activity against Gram-positive cocci
The in vitro activity of various antimicrobials against MSSA, MRSA (including HA-MRSA and CA-MRSA), S. epidermidis [including methicillin-susceptible (MSSE) and methicillin-resistant (MRSE)], S. pneumoniae, S. agalactiae, S. pyogenes, E. faecalis and Enterococcus faecium is displayed in Table 2 . Limited resistance was observed among S. aureus (MSSA), with the exception of clarithromycin, the fluoroquinolones and clindamycin. With S. pneumoniae, limited resistance was observed, with the exception of cefuroxime (4.3%), clarithromycin (16%), clindamycin (6.2%), doxycycline (3.8%), penicillin (MIC 90 of 0.25 mg/L, with 4.5% resistance) and trimethoprim/sulfamethoxazole (8.7%). Isolates were uniformly susceptible to linezolid and vancomycin. Telavancin was very active against S. pneumoniae, with an MIC 90 of ≤0.06 mg/L. Susceptibility testing with clarithromycin and clindamycin suggested that 40% of isolates displayed altered target site resistance to macrolides, while 60% of S. pneumoniae demonstrated efflux-mediated resistance to macrolides. Both S. pyogenes and S. agalactiae were extensively susceptible to the tested antimicrobials, although clarithromycin resistance was noted in 9.7% and 25.4% of isolates, respectively. Against E. faecalis and E. faecium, ciprofloxacin/levofloxacin resistance was seen in 33.6%/33.5% and 90.6%/89.2% of isolates, respectively. E. faecalis and E. faecium were 100% susceptible to daptomycin; additionally, linezolid and tigecycline were very active. Twenty-two percent (61/271) of E. faecium were 
Antimicrobial activity against Gram-negative bacilli
The in vitro activity of various antimicrobials against E. coli (including ESBL-producing isolates), P. aeruginosa, Klebsiella pneumoniae, H. influenzae, Enterobacter cloacae, P. mirabilis, Klebsiella oxytoca, S. marcescens, S. maltophilia, Enterobacter aerogenes, Citrobacter freundii and Acinetobacter baumannii is displayed in Table 3 . For E. coli, resistance rates .20% were noted for trimethoprim/sulfamethoxazole, ciprofloxacin and levofloxacin. The most active agents against E. coli were amikacin, cefepime, ceftazidime, doripenem, ertapenem, meropenem, nitrofurantoin, piperacillin/tazobactam and tigecycline. ESBLproducing E. coli displayed elevated resistance rates to ciprofloxacin, trimethoprim/sulfamethoxazole and gentamicin. All ESBL-producing E. coli were susceptible to doripenem and meropenem, while ertapenem (97.4% susceptible), amikacin (95.7% susceptible), nitrofurantoin (94.4% susceptible) and tigecycline (99.6% susceptible) were very active.
The most active agents tested against P. aeruginosa were colistin (polymyxin E), amikacin, doripenem, piperacillin/ tazobactam, ceftazidime and meropenem. The resistance of P. aeruginosa to fluoroquinolones and gentamicin was high (15%-25%). For K. pneumoniae, meropenem, doripenem, ertapenem and amikacin demonstrated susceptibility rates .99%. All agents were active against H. influenzae, except ampicillin and trimethoprim/sulfamethoxazole with 17.2% and 13.1% resistance, respectively. With E. cloacae, .99% of isolates were susceptible to amikacin, meropenem, doripenem and cefepime. All P. mirabilis isolates were susceptible to cefepime, doripenem, ertapenem, meropenem and piperacillin/ tazobactam. With S. marcescens, .98% of isolates were susceptible to meropenem, doripenem, ertapenem, cefepime, ceftazidime and amikacin. With K. oxytoca, all agents were very active, except cefazolin with 56.1% resistance. The most active agents tested against S. maltophilia were trimethoprim/ sulfamethoxazole and levofloxacin, with 86.6% and 66.9% susceptibility, respectively. Tigecycline demonstrated good activity against S. maltophilia, with MIC 50 and MIC 90 values of 2 and 8 mg/L, respectively. The most active agents tested against A. baumannii were amikacin, meropenem, colistin and levofloxacin, with susceptibility rates .93% for all four agents. 
Discussion
The CANWARD study is the first national, ongoing, prospective, Health Canada-endorsed surveillance study assessing antimicrobial activity against pathogens from Canadian hospitals, including hospital clinics, emergency rooms, medical and surgical wards and ICUs. 5, 6 A total of 27123 pathogens were collected between 2007 and 2011 inclusive, 83.9% of which underwent susceptibility testing ( Table 1 ). The most active antimicrobial agents (based upon MIC data only) against Gram-positive organisms were vancomycin, linezolid, daptomycin, telavancin and tigecycline. It should be mentioned that listing agents as most active based solely upon MIC is not accurate, as potency depends upon both the agent's pharmacokinetics as well as in vitro susceptibility (i.e. pharmacodynamics). However, as an in vitro susceptibility study, the activity of antimicrobial agents was evaluated in this fashion.
In this study, vancomycin was active against MSSA and MRSA, with only one isolate (0.08%) of MRSA displaying a vancomycin MIC of 4 mg/L. This is consistent with previous data reporting that vancomycin continues to be active against MSSA and MRSA in Canada, the USA and internationally. 5,6,14 -17 Vancomycin MIC creep was not observed in this study. Vancomycin was less active against MSSE and MRSE compared with MSSA and MRSA, which is consistent with previous reports. 5,6,16,18 -20 In this study, as well as with previous data, vancomycin continues to be very active against all Streptococcus spp. 5, 6, 16, 18, 20 Vancomycin was less active against E. faecalis and E. faecium, with 0.1% and 22.4% of strains demonstrating resistance, respectively. As has been reported elsewhere, the predominant ( 90% in this study) VRE genotype in North America continues to be vanA.
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Linezolid was active against MSSA, MRSA, MSSE, MRSE and Streptococcus spp., with all isolates demonstrating linezolid susceptibility. Linezolid's continued excellent activity against these isolates is consistent with the current literature. 6, 15, 18, 19 Linezolid was less active against E. faecalis and E. faecium, with 4.5% and 11.2% of strains demonstrating intermediate resistance, respectively. This low rate of linezolid non-susceptibility in E. faecalis and E. faecium is consistent with previous reports. 6,15,18 -20 Daptomycin was active against MSSA, MRSA, MSSE and MRSE, with all isolates demonstrating daptomycin MICs ≤1 mg/L. Daptomycin's excellent activity against MSSA/MRSA and MSSE/MRSE has been previously documented. 6, 14, 16, 17, 21 In addition, it has been recently reported that daptomycin displays excellent activity (MIC 90 of 0.5 mg/L) and maintains bactericidal activity against MRSA with vancomycin MICs of 2 mg/L, many of which are heteroresistant vancomycin-intermediate-resistant S. aureus.
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As has been previously reported, daptomycin was active against Streptococcus spp. 6, 16, 18 Daptomycin was also very active against E. faecalis, E. faecium and VRE. Daptomycinresistant Enterococcus spp. continue to be rare 16, 17 and have not been documented in Canada. From these data, it is clear that daptomycin is a very active agent against all Gram-positive organisms causing infections in Canadian hospitals.
In this study, both telavancin and tigecycline were active against MSSA, MRSA, MSSE, MRSE and Streptococcus spp., as has been demonstrated previously. 6,14,23 -25 Tigecycline was also very active against E. faecalis, E. faecium and VRE. Thus, both of these agents show good activity against Gram-positive pathogens causing infections in Canadian hospitals.
The most active (based upon MIC) agents against the Gramnegative bacilli obtained from Canadian hospitals were amikacin, cefepime, doripenem, ertapenem (excluding P. aeruginosa), meropenem, piperacillin/tazobactam and tigecycline (excluding P. aeruginosa) ( Table 3) . Zhanel et al.
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In this study, amikacin was very active against E. coli (including ESBL-producing strains). Likewise, amikacin proved to be very active against all other Enterobacteriaceae tested (Table 3) . Against P. aeruginosa and A. baumannii, amikacin was one of the most active agents tested. The excellent activity of amikacin and other aminoglycosides against both Enterobacteriaceae as well as non-fermenters isolated from patients in hospitals, including in the ICU, is not surprising, as the reduced usage of aminoglycosides in favour of fluoroquinolones over the last 15 years has resulted in maintained or even increased activity of aminoglycosides in the setting of increasing fluoroquinolone resistance. 3, 26 Thus, amikacin represents a potential option for the treatment of infections caused by Gram-negative bacilli resistant to other less toxic agents.
In this study, we report that cefepime, doripenem, ertapenem, meropenem and piperacillin/tazobactam were very active against Gram-negative bacilli isolated from patients in Canadian hospitals. These agents were active against Enterobacteriaceae, including E. coli (only doripenem, ertapenem and meropenem were active against ESBL-producing strains, due to the presence of multiple b-lactamases per bacterial cell). Among P. aeruginosa, resistance rates for piperacillin/tazobactam, meropenem and cefepime were less than 10%. Previous investigators have reported the ongoing excellent activity of these agents against Gram-negative bacilli isolated from hospitalized patients. 3, 27 In this study, the activity of doripenem was similar to that of meropenem, except that it was more active against P. aeruginosa and A. baumannii. This is consistent with previous data. 6 Colistin was found to be very active against E. coli (including ESBL-producing strains). Colistin was also very active against Klebsiella spp., P. aeruginosa and A. baumannii. These data are consistent with other recent reports of the promising potential of polymyxins for Gram-negative bacilli such as P. aeruginosa and A. baumannii. 28, 29 In this study, tigecycline demonstrated excellent activity against E. coli (including ESBL-producing strains) and was also active against other Enterobacteriaceae, including K. pneumoniae, E. cloacae, S. marcescens and K. oxytoca (Table 3) . These data are consistent with recent studies showing the excellent activity of tigecycline against Gram-negative bacilli, including MDR strains. 30, 31 Tigecycline was not active against P. mirabilis and P. aeruginosa. As with previous studies, tigecycline displayed good activity against S. maltophilia and A. baumannii, organisms frequently resistant to other antimicrobial classes (Table 3) . 31, 32 These data support the potential use of this agent for the treatment of infections caused by non-Pseudomonas Gram-negative bacilli in hospitalized patients. 30 -32 The CANWARD study has several limitations, including the fact that we cannot be certain that all clinical specimens represented active infection. In the CANWARD study, the medical centres were asked to submit only clinically significant specimens from patients with a presumed infectious disease; however, this interpretation cannot be rigorously controlled by the coordinating site. Although not all of the isolates may represent actual infection, we believe the vast majority were clinically significant isolates as all surveillance swabs, duplicate swabs, eye, ear, nose and throat swabs and genital cultures were specifically excluded from the study, and the primary medical centres agreed to the study criteria. Another limitation is that we do not have admission date data for each patient/clinical specimen; thus we are not able to provide a more accurate description of community versus nosocomial onset. Finally, antimicrobial susceptibility testing was not performed for all commercially available antimicrobial agents due to lack of space on the custom-designed susceptibility panels utilized. It is recognized that data on antimicrobials such as cefotaxime, imipenem, tobramycin and others would be beneficial, as different hospital formularies stock these and other antimicrobials not tested in this study.
In conclusion, E. coli, S. aureus, P. aeruginosa, S. pneumoniae, K. pneumoniae and Enterococcus spp. are the most common pathogens in Canadian hospitals. Susceptibility rates for E. coli were highest with meropenem, ertapenem, piperacillin/tazobactam and tigecycline. Susceptibility rates for P. aeruginosa were highest with amikacin, colistin, meropenem, piperacillin/tazobactam and ceftazidime. All MRSA were susceptible to daptomycin, linezolid and telavancin and 99.9% were susceptible to vancomycin.
